Biomarker-based endotypes in inflammatory skin diseases currently guide drug development rather than routine clinical prescribing, according to guidelines published in November 2026. While biological pathways are mapped in conditions like atopic dermatitis, psoriasis, and hidradenitis suppurativa, treatment selection relies on traditional clinical factors.
Inflammatory skin diseases have been categorized by visible features such as lesion morphology, distribution, and severity. Network meta-analysis data evaluate multiple interventions across thousands of patients. Findings for authorized choices rely upon a network meta-analysis encompassing 28,686 participants, 149 trials, and 75 interventions, drawing from a literature search refreshed up to November 2022.
Upadacitinib 30 mg emerged as the most effective option in atopic dermatitis network evaluations. It achieved EASI score differences compared to placebo of -13.99, ahead of upadacitinib 15 mg at -11.43 and dupilumab at -10.72.
That high efficacy comes with increased adverse events, including 108 more adverse events per 1,000 patients treated with upadacitinib 30 mg and 85 more with abrocitinib 200 mg. Skin viral infections occur more frequently with high-dose JAK inhibitors, showing odds ratios of 2.81 for abrocitinib 200 mg and 2.58 for upadacitinib 30 mg.
Within the network meta-analysis, upadacitinib 30 mg carried both the highest efficacy and the greatest risk of harm. Dupilumab and anti-interleukin (IL)-13 therapies presented moderate effectiveness paired with reassuring safety profiles.
Dupilumab, lebrikizumab, and tralokinumab demonstrated intermediate efficacy alongside favorable safety profiles. Class-wide safety signals indicate that conjunctivitis occurs at similar rates across dupilumab, lebrikizumab, and tralokinumab with odds ratios of 2.88, 2.58, and 2.46 respectively, pointing to IL-13 blockade as the primary underlying cause. Long-term safety is open to question.
Translating Molecular Subtypes Into Prescribing Choices
Data-driven analyses reveal substantial heterogeneity within patient populations. Serum biomarkers identify four distinct clusters in adults and four in children with atopic dermatitis, sharing minimal overlap between age groups.
For psoriasis, safety and efficacy data alone do not suffice to distinguish between medications, making patient preference the ultimate deciding element. Treatment selection remains driven by patient preference, infection risk, and comorbidities rather than molecular profiling.
Bimekizumab use involves documented rates of oral candidiasis in 10 percent to 13 percent of patients, alongside newly diagnosed inflammatory bowel disease in a fraction of patients under 1 percent.
Before starting therapy, the guideline advises assessing for inflammatory bowel disease via medical history. It directs patients to a gastroenterologist if symptoms develop, even though this step is categorized as a may be considered
recommendation.
Comorbidities Guide Drug Selection Amid Monitoring Requirements
Therapeutic decision-making in hidradenitis suppurativa lacks reliable response predictors. Clinicians rely on patient comorbidities such as inflammatory bowel disease to guide drug selection.
Deucravacitinib, a selective TYK2 inhibitor, introduces specific monitoring requirements due to reported upper respiratory tract infections, herpes simplex, oral ulcers, folliculitis, acne, and potential creatine kinase elevations. Long-term safety follow-up is necessary to determine whether the molecule shares the specific safety risks associated with JAK inhibitors.
While biological mechanisms have been mapped, clinical trials validate the success of their inhibition.
Choosing a therapy for an individual patient continues to rely on classic considerations: severity, anatomical site, comorbid conditions, safety profiles, and patient choice.